Evaluation of Asprosin Hormone in Hypothyroidism Patients
DOI:
https://doi.org/10.30526/36.2.3008Keywords:
Asprosin ,Thyroid Dysfunction, Hypothyroidism, Lipid Profile.Abstract
Asprosin was a novel adipokine that was released by white adipose tissue. It was activated by fasting and attracted to the liver, which allowed the liver to rapidly release glucose into the bloodstream. White adipose tissue was the source of asprosin. When people go on a fast, their blood sugar levels drop, which causes levels of the hormone asprosin to rise. It does this by binding to a G-protein-coupled receptor in the liver known as OR4M1, which in turn activates a cascade that involves the G -protein-cAMP-PKA pathway. Because of this, the glucose that is stored in the liver is released. We anticipate that by investigating the changes that occur in asprosin levels in hypothyroidism patients, we will be able to make a significant addition to the area and fill a gap that has been left unexplored in the anther researches. Eighty patients (women ) ranging in age from 25 to 65 were collected from the National Diabetes Center Al-Mustansiriyah University (Iraq) for the purpose of this study, which was designed as a cross-sectional study to determine the concentrations of serum ( asprosin, thyroid hormone T3 T4 TSH, Fasting blood glucose FBG, and lipid profile( Total cholesterol TCho,Triglycride TG,high density lipoprotein HDL, Low density lipoprotein LDL, Very low density lipoprotein VLDL) . In the period beginning in December 2021 and continuing until March 2022. This particular study included a total of 80 participants, 40 of whom had thyroid disease (hypothyroidism), and 40 healthy individuals who served as controls. When compared to the control group, the findings of this study indicate that the levels of total cholesterol TC, triglycerideTG, and low-density lipoprotein (LDL) have dramatically increased, whilst the levels of HDL have significantly decreased . A substantial increase in (Fasting blood glucose FBG and Body mass index BMI) levels was also observed, in contrast to the group that served as the control. In patients with hypothyroidism, the levels of thyroid-stimulating hormone TSH were considerably greater, while the levels of T3 were significantly lower. The T4 level, however, revealed no significant differences when compared to the control group. In addition, the level of asprosin was found to be high in the hypothyroidism group only contrast to the control group that participated in this research.
This current study indicates the hormone asprosin could be helpful early diagnosis in monitoring hypothyroidism patients. hormone asprosin is a marker of glucose homeostasis, so it may be surrogate novel biomarker for all other traditional biomarkers for the prediction of risk factors of diabetes and thyroid dysfunction
References
Al-Shaibani, AB,; Al-A’araji, SB.; Al-Mofarji, ST. Studying association between thyroid disorders and Helicobacter pylori infection in Iraqi Patients. Baghdad Science Journal. 2014,11,1528-14.
Toyib, S.; Kabeta, T.; Dendir, G.; Bariso, M.; Reta, W. Prevalence clinical presentation and patterns of thyroid disorders among anterior neck mass patients visiting Jimma Medical Center, Southwest Ethiopia. Biomed. J. Scient. Tech. Res. 2019,18,13431-5.
Chiovato, L.; Magri, F.; Carlé, A. Hypothyroidism in context: where we’ve been and where we’re going. Advances in therapy. 2019,36,47-58.
Kar, K.; Sinha, S. Variations of adipokines and insulin resistance in primary hypothyroidism. Journal of clinical and diagnostic research: JCDR. 2017,11,BC07.
Romere, C.; Duerrschmid, C.; Bournat, J.; Constable, P.; Jain, M.; Xia, F.;Saha, PK.; Del Solar, M.; Zhu, B.; York, B.; Sarkar, P. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016, 165,566-79.
Hoffmann, JG.; Xie, W.; Chopra, AR. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes. 2020, 1;69,559-66.
Leonard, AN.; Shill, AL.; Thackray, AE.; Stensel, DJ.;Bishop, NC. Fasted plasma asprosin concentrations are associated with menstrual cycle phase, oral contraceptive use and training status in healthy women. European journal of applied physiology. 2021,121,793-801.
Naiemian, S.; Naeemipour, M.; Zarei, M.; LariNajafi, M.; Gohari, A.; Behroozikhah, MR.; Heydari, H.; Miri, M. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetology& Metabolic Syndrome. 2020, 12,1-8.
Luís, C.; Fernandes, R.; Soares, R.; von Hafe, P. A state of the art review on the novel mediator asprosin in the metabolic syndrome. Porto Biomedical Journal. 2020, 5(6).
Janoschek, R.; Hoffmann, T.; Morcos, YA.; Sengle, G.; Dötsch, J.; Hucklenbruch-Rother ,E. Asprosin in pregnancy and childhood. Molecular and Cellular Pediatrics. 2020, 7,1-5.
Sue, LY.; Leung, AM. Levothyroxine for the treatment of subclinical hypothyroidism and cardiovascular disease. Frontiers in endocrinology. 2020, 11,591588.
Hashim, MF.; Dawood, SA.; Ahmad, YI. Evaluation of some Biochemical parameters in serum patients with thyroid gland dysfunction. Basrah J. Sci. 2018, 36,42-51.
Cicatiello ,AG.; Di Girolamo, D.; Dentice, M. Metabolic effects of the intracellular regulation of thyroid hormone: old players, new concepts. Frontiers in Endocrinology. 2018 , ,9,474.
Wang, CY.; Lin, TA.; Liu, KH.; Liao, CH.; Liu, YY.; Wu, VC.; Wen, MS.; Yeh, TS. Serum asprosin levels and bariatric surgery outcomes in obese adults. International journal of obesity. 2019, 43,1019-25.
Deng, X.; Zhao, L.; Guo, C.; Yang, L.; Wang, D.; Li, Y.; Xia, H.; Wang, C.; Cai, Z.; Li, L.; Zhao, Z. Higher serum asprosin level is associated with urinary albumin excretion and renal function in type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020, 13,4341.
SünnetçiSilistre, E.; Hatipoğl, HU. Increased serum circulating asprosin levels in children with obesity. Pediatrics International. 2020, 62,467-76.
Wang, Y.; Qu, H .; Xiong, X .; Qiu, Y.; Liao, Y.; Chen, Y.; Zheng, Y.; Zheng, H. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators of inflammation. 2018, 7,2018.
Alan, M .; Gurlek, B .; Yilmaz, A .; Aksit, M.; Aslanipour, B.; Gulhan, I.; Mehmet, C.; Taner, CE. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology. 2019, 4,35,220-3.
Groener, JB.; Valkanou, A.; Kender, Z.; Pfeiffenberger, J.; Kihm, L.; Fleming, T.; Nawroth, PP.; Kopf, S. Asprosin response in hypoglycemia is not related to hypoglycemia unawareness
but rather to insulin resistance in type 1 diabetes. PLoS One. 2019, 14,e0222771.
El Amrousy, D.; El-Afify, D.; Salah, S. Insulin resistance, leptin and adiponectin in lean and
hypothyroid children and adolescents with obesity. BMC pediatrics. 2022, 22,1-6.
Duntas, LH.; Brenta, G. A renewed focus on the association between thyroid hormones and
lipid metabolism. Frontiers in endocrinology. 2018, 9,511.
Mullur, R .; Liu, YY .; Brent, GA. Thyroid hormone regulation of metabolism. Physiological
reviews. 2014, 94, 355-382.
Du, FM.; Kuang, HY.; Duan, BH.; Liu, DN.;Yu, XY.Effects of thyroid hormone and depression on common components of central obesity. Journal of International Medical Research. 2019, 47,3040-9.
Åsvold, BO.; Bjøro, T.; Vatten, LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J ClinEndocrinolMetab. 2009, 94,5023–7.
Ameen, MR.; Sulaiman, DM.; Muho, KH. Serum Asprosin Levels in Women with Polycystic
Ovary Syndrome in Duhok City, Kurdistan Region of Iraq. Journal of Life and Bio Sciences
Research, 2021, 2, 36-41.
Ugur, K.; Aydin, S. Saliva and blood asprosin hormone concentration associated with obesity.
International journal of endocrinology. 2019, 27,2019.
Aati, EK.; Al-Ali, ZA. Effect of hypothyroidism on lipid profile in women at Misan City/Iraq.
Medical Journal of Babylon. 2020, 17,1.
Alsalmi,WM .; Shaglouf, LH.; Azab, AE. Correlation Between Hypothyroidism,
Hyperthyroidism, and Lipid Profile in Thyroid Dysfunction Patients. Clin Med J. 2018, 4,6-14
Yuan, M .; Li, W.; Zhu, Y.;Yu, B.; Wu, J. Asprosin: a novel player in metabolic diseases.
Frontiers in endocrinology. 2020, 11,64.
Alobaidi, MB.; Al-Samarrai, RR. Correlation between Serum Asprosin Level And Oxidative
Stress in Iraqi Patients with Type II Diabetes Mellitus. Systematic Reviews in Pharmacy.
,11,1729-33.
Mazur-Bialy,AI. Asprosin—A Fasting-Induced, Glucogenic, and OrexigenicAdipokine as a
New Promising Player. Will It Be a New Factor in the Treatment of Obesity, Diabetes, or Infertility? A Review of the Literature. Nutrients. 2021, 13,620.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Ibn AL-Haitham Journal For Pure and Applied Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
licenseTerms